Administration in Experimental Contexts BPC-157 is typically administered via injection in research environments
Short-term protocols (1216 weeks) at standard doses carry minimal toxicity risk, but long-term use beyond 6 months lacks human safety data as of 2026
Additional information Details Original published date: Media and public enquiries Media Enquiries: Health Canada 613-957-2983 [email protected] Public Enquiries: 613-957-2991 1-866-225-0709 [email protected] Get notified Receive emails about new and updated recall and safety alerts.
Neurological symptomsincluding balance problems, confusion, or peripheral neuropathyrequire urgent assessment, as prolonged deficiency can cause irreversible nerve damage
Your healthcare provider will monitor your progress and adjust your plan as needed
Observations in research suggest that significant changes in skin density, texture, and scar appearance can take 8-12 weeks or longer, consistent with the natural skin remodeling cycle